TRANS GENIC GROUP INC.【JP:2342】Stock Price

Transgenics Group operates primarily through two business segments. First, the "Drug Discovery Support Business" provides seamless services across all stages of drug development, from initial research through clinical trials. Specific offerings include contract manufacturing of genetically modified mice, antibody production, contract analysis and synthesis of glycans, and contract pharmacology and safety testing services for pharmaceuticals, pesticides, and food-related substances.

Second, the "Investment and Consulting Business" is led by TG Business Services Inc. This segment provides advisory and support services for new business development through M&A, as well as business succession and business restructuring. Specific activities include retail and wholesale of electrical products, import and sales of Western tableware, B2C and B2B e-commerce, development and sales of information and communication equipment, import and sales of auxiliary materials for laminated glass and glass processing equipment, import and sales of printer toner, and planning and sales of rice bags.

Transgeic Group's management philosophy is to contribute to the future and realize the health and prosperity of people worldwide. Under this philosophy, the Group aims for growth by responding quickly to changes in the business environment and appropriately evolving its business model.

The company operates two core business pillars: drug discovery support services and investment and consulting services, through which it pursues sustainable growth. In drug discovery support services, the company strengthens the provision of high-value-added services that differentiate it from competitors, covering everything from basic research to clinical trials.

In investment and consulting services, the company strengthens and diversifies its revenue base through M&A and business succession. In particular, it actively invests in the business succession and revitalization sector, aiming to achieve results in a short timeframe.

Transgeic Group targets revenue of 13,500 million yen and operating profit of 150 million yen for the fiscal year ending March 2026. Through this, the company aims to realize sustainable growth and increased corporate value.

In drug discovery support services, the company enhances competitiveness through testing using genetically modified mice and the introduction of new testing methods. In investment and consulting services, the company improves profitability while addressing cost increases due to yen depreciation.